Deals Illumina’s cancer diagnostics spinout, Grail, came out of stealth less than two years ago but has raised some big money since. Its series B round has been increased from $973m to $1.2bn according to a securities filing, though there’s been no confirmation as to who joined the round, which already included Tencent, Amazon, Bristol-Myers … Continue reading "27 November 2017 – $1.2bn in Grail’s Series B"